20 Eylül 2023 Çarşamba
3 Ways to Prevent Cancer
He has been working as a medical oncology and hematology specialist and director of medical oncology at Anadolu Medical Center since 2005.
Ankara University Medical School, Ankara 1971
GATA Medical School, Ankara 1979
Wadley Institutes of Molecular Medicine, Granville-Morton Cancer Hospital, Medical Oncology and Hematology Sub-specialties, 1982
GATA Medical School, Medical Oncology Clinic, Ankara 1984
GATA Medical School, Medical Oncology Clinic, Ankara 1989
GATA, Medical Oncology and Hematology Clinics, Istanbul 2001
Prof. Necdet Üskent, graduated from Ankara University Medical School. He completed his residency training in internal medicine at Ankara GATA Medical School. He has done his clinical fellowship training in Medical Oncology and Hematology in the USA, Dallas, Texas. He took part in the Bone Marrow Transplantation team that performed the first transplantation in Turkey. At different times and for long terms, he served as visiting lecturer at Westminster Hospital Charing Cross, Hammersmith, Royal Free and University College Hospital, in London UK, and at Basel Cantone Hospital in Switzerland. Passing the exam organized by European Society of Medical Oncology (ESMO), he obtained the European Medical Oncology Certificate. Being one of the 7 founding members of The Turkish Society of Medical Oncology, Prof. Üskent was also a founder of Turkish Oncology Group (TOG).
After serving as director of Istanbul GATA Medical Oncology and Hematology Clinics for 13 years, Prof. Üskent later worked as lecturer – professor at Kadir Has University (Bilim University), Medical School, Internal Medicine Clinic. He also served as medical oncology and hematology specialist and lecturer at Florence Nightingale Hospital, a hospital associated to the university. Prof. Üskent who started to work at Anadolu Medical Center, Medical Oncology Clinic in 2005 has been working as a medical oncology and hematology specialist and also director of medical oncology at Anadolu Medical Center since 2010.
1. N. Üskent, M. Danacı, M. Özel, İ. Öztek, Z. Altınok, B. S. Cebeci, M. Altın, S. Yürütken, N. Doğan, F. Karslı: Complete response to alpha interferon 2b in classic (AIDS non-related) Kaposi’s Sarcoma and an unusual toxicity of interferon. Kanser. Türk J Cancer. 1991; 21(2): 83-88.
2. N. Üskent, M. Danacı, M. Özel: New horizons in cancer treatment. Clinical use of endogenous colony-stimulating factors (CSF). Turkish Journal of Oncology. 1991; 6 (3-4): 1205-1210.
3. M. Danacı, N. Üskent, K. Doğruöz, İ. Öztek, Z. Altınok, M. Özel: A rare case: Toxic purpura due to topical use of etofenamate. Sendrom1991;3:19-22.
4. N. Üskent, M. Danacı, M. Özel, H. Tor, G. Öztürk, İ. Öztek, F. Karslı, T. Çelenk, Y. Z. Yergök: Ovarian cancer metastasis to thyroid and cervical lymph node. Turk J Cancer. 1992;22(1):39-43. 5- Our Results with Combination of FU, Etoposide and High Dose Leucoverine (FEL). GATA Bulletin 34: 563-568, 1992.
5. Üskent N. Danacı M. Haksever H. In Advanced Colorectal cancers
6. N. Üskent, M. Danacı, M. Özel, M. Yaylacı, H. Tor: Treatment of severe aplastic anemia with cylosporin-A and high dose methylprednisolone. Marmara Medical Journal. 1992;5(1):27-30.
7. M. Danacı, L. Dumanhan, M. Özel, H. Tor, N. Üskent: The effect of gemfibrozil in diabetic hyperlipidemias. GATA Bulletin. 1992; 34: 285-295.
8. H. Tor, M. Yaylacı, N. Üskent, A. Acaroğlu, M. Danacı, M. Özel: The value of beta 2 microglobulin in the staging and early diagnosis of diabetic nephropathy. GATA Bulletin. 1992; 34: 691-704.
9. N. Üskent, Z. Mete, M. Danacı, M. Özel, H. Tor, İ. Göçmen, N. Haksever: Our results with high dose intravenous immuglobulin G administration in acute and chronic idiopathic thrombocytopenic purpura. GATA Bulletin. 1992; 34: 859-865.
10. S. Hülagü, İ. Dinç, M. Altın, M. Danacı, M. Özel, Z. Çankır, G. Öztürk, M. Yaylacı, N. Üskent, S. Yürütken: Evaluation of the effects of octreotide on portal hemodynamics using pulsed Doppler ultrasonography in patients with chronic liver disease. Marmara Medical Journal. 1993; 6(4): 131-136.
11. Öztürk A. Üskent N. The value of serum protein C level in myocardial infarction. Marmara Medical Journal. 6:3,88-90, 1993.
12. M. Danacı, S. Gül, M. Özel, M. Yaylacı, N. Üskent, S. Yürütken: Evaluation of re-prescription problem in military hospitals. GATA Bulletin. 1994; 36: 329-35.
13. Yaylacı M. Öztürk A. Üskent N. Graft-Versus –Host Disease. Haseki Medical Bulletin. 33:237-241, 1994.
14. Yaylacı M. Öztürk A. Üskent N. Granulocyte-macrophage Colony-Stimulating Factor (GM-CSF). Interaction with other cytokines and clinical uses. Türkiye Klinikleri Medical Sciences Journal. 14:373-377,1994.
15. M. Danacı, M. Özel, M. Yaylacı, H. Baloğlu, N. Üskent: Demonstration of the relationship of Epstein-Barr virus with Hodgkin’s disease and non-Hodgkin lymphomas. GATA Bulletin. 1995; 37: 489-96.
16. Öztürk A. Üskent N. Activated Protein –C Resistance in malignancy. Acta hematologica, 1995.
17. Öztek I, Baloğlu H, Üskent N, Kartaloğlu Z, Uçmaklı E, Aydilek R, Dorkip O, Yaylacı M, Özel M., "Chemotherapy- and radiotherapy-induced cytologic alterations in the sputum of patients with inoperable lung carcinoma. Role in follow-up. ", Acta Cytol. 1996 Nov-Dec;40(6):1265-71.
18. O, Kozluca, Olcay E, Sürücü S, Güran Z, Kulaksız T, Üskent N. 1996. "Prevention of doxorubicin induced cardiotoxicity by catechin. " Cancer Lett 99 (1): 1-6.
19. M, Danacı, Gül S, Yazgan Y, Hülagü S, Üskent N. 1996. "Budd-Chiari syndrome as a complication of Behçet's syndrome. A case report. " Angiology 47 (1): 93-5.
20. H, Yazıcı, Şengün Z, Aktan M, Aktuğlu G, Üskent N, Dalay N. 1997. "Clinical use of the bcr/abl probe test in the evaluation of chronic myeloid leukemia patients. " Journal of experimental & Clinical Cancer Research : 16 (1): 105-9. 1997.
21. Altaş A. Öztürk A. Üskent N. The value of serum IL-6 in non-Hodgkin lymphomas. GATA Bulletin 39: 15-19, 1997.
22. Cebeci B. İngözbay Y. Öztürk A. Üskent N. :Activated Protein C resistance in myocardial infarction. Marmara medical journal. 10:84-86, 1997.
23. Öztürk A. Sezer M. Üskent N. The results of intensive immunosuppression with anti-thymocyte globulin and cyclosporine a in severe apalstic anemia. Marmara Medical Journal. 10: 101-103, 1997.
24. Öztürk A. Kandemir G. Üskent N. ABDIC Regimen in Relapsed/Refractory hodgkin’s Diseasecal journal. 10:135-137, 1997.
25. Öztürk A. Kandemir G. Üskent N. Activated Protein C Resistance and Hemostatic Balance in Malignancy. Turkish Journal of Oncology. 12:1,24-26, 1997.
26. Öztürk A. Üskent N. Our results with CVPD protocol in Acute Lymphoblastic Leukemia. GATA Bulletin. 39:159-162, 1997.
27. Öztürk A. Sezer M. Üskent N. The value of serum interleukin-6 level in multiple myeloma. Turkish Journal of Oncology. 12:1,21-23, 1997.
28. Öztürk A. Kandemir G. Yaylacı M. Üskent N. High dose chemotherapy supported by Thawed Autologous Peripheral Stem Cell. Klinik gelişim. 10: 173-176,1997
29. Öztürk A. Günay A. Budak T. Akoğlu T. Üskent N. Activated Protein C Resistance in Chronic Myeloid Leukemia. Klinik Gelişm. 10: 147-149, 1997.
30. T, Budak-Alpdoğan, Demirçay, Alpdoğan O, Direskeneli H, Ergün T, Öztürk A, et al. "Skin hyperreactivity of Behçet's patients (pathergy reaction) is also positive in interferon alpha-treated chronic myeloid leukaemia patients, indicating similarly altered neutrophil functions in both disorders." British journal of rheumatology 1998;37 (11): 1148-51.
31. A, Öztürk, Günay A, Üskent N. 1998. "Therapeutic efficacy of recombinant interferon-alpha in polycythaemia vera. " Acta haematologica 99 (2): 89-91. i:40817.
32. Kandemir EG, Yaylacı M, Öztürk A, Üskent N. Docetaxel-induced radiation recall dermatitis. THOD 1999; 9(2):111–3.
33. Kandemir G. Yaylacı M. Üskent N. Vinorelbine-mitomycin-c combination in previously untreated metastatic breast cancer. Turkish Journal of Oncology 13: 120-123, 1999.
34. Öztürk A. Sezer M. Üskent N. The effects of HMG CoA reductase inhibitors on platelet aggregation. Klinik Bilimler. 5:2,161-164, 1999.
35. Karadoğan, B. Artmen, M. Bayık, Ş. Kansoy, E. Ovalı, A. U. Ural, O. İlhan: National survey of peripheral blood stem cell (PBSC) apheresis complications in Turkey 1998. Bone Marrow Transplantation 25: p-906, 2000.
36. N. Üskent, A. Öztürk, Ö. Arslan, S. B. Omay, A. Ünal, S. Anak, S. Paydap, S. Kalayoğlu, F. Arpacı, S. Cadurgan, E. Ovalı, S. Kensoy, M. Bayık, A. U. Ural, Z. Gülbaş, O. İlhan: Autologous peripheral blood stem cell collection. 1998 activity of Turkey. Bone Marrow Transplantation 25: 911, 2000.
37. Yaylacı M. Türken O. Üskent N. Experimental demonstration of cytoprotective efficacy of amifostine in reducing cardiotoxicity due to doxorubicin. Turkish Journal of Oncology. 15(14), 2000.
38. Günay A, Öztürk A, Budak T, Özbek U, Üskent N. Activated protein C resistance in polycythemia vera Turk J Haematol 2000 18(3):157-164.
39. O, İlhan, Üskent N, Arslan O, Arat M, Özkalemkaş F, Öztürk G, et al. 2000. "National survey of hemapheresis practice in Turkey . Transfusion science 22 (3): 195-201. 2000.
40. N, Köksal, Müftüoglu T, Günerhan Y, Üskent N. "Complete remission of the liver metastases of anorectal malignant melanoma with regional chemotherapy: a case report. " Hepato-gastroenterology. 2000 ; 47 (33): 612-4.
41. O. Türken, B. Orhan, A. Öztürk, D. Etiz, M. Yaylacı, N. Üskent; Patients with Myelodysplastic Syndromes Benefit From Therapy with Amifostine, Pentoxifylline and Ciprofloxacin with Dexamethasone. Blood 98, 24bb, 2001.
42. O. Türken, A. Öztürk, B. Orhan, G. Kandemir, M. Yaylacı, N. Üskent; A Case Report: Large Granular Cell Leukemia/Lymphoma. Blood 98, 207b, 2001.
43. O. Türken, B. Orhan, A. Öztürk, D. Etiz, M. Yaylacı, N. Üskent; Patients with Myelodysplastic Syndromes Benefit From Therapy with Amifostine, Pentoxifylline and Ciprofloxacin with Dexamethasone. Blood 98, 24bb, 2001.
44. Yaylacı M, Orhan B, Etiz D, Öztürk A, Çermik H, Türken O, Üskent N. Primary Angiosarcoma of the Breast. Journal of Balkan Union of Oncology. 6: 203-205, 2001.
45. Üskent N, Orhan B. Malt Lymphomas Actual Hematology -Onkoloji Derleme Dergisi. 3: 37-42 2001.
46. OrhanT, Öztürk A, Yaylacı M, Orhan B, Üskent N. High-dose chemotherapy with non-cryopreserved autologous peripheral stem cell transplantation in refractory/relapsed testicular carcinoma, single center results. Turkish Journal of Cancer. 31: 72-77,2001.
47. Dincbas FO, Koca S, Altınel A, Hancılar T, Çavuşoğlu M, Turhal S, Üskent N, Özgüroğlu M, Okkan S. Continuous accelerated hyperfractionated radiotherapy (CHART) plus chemotherapy (CT) with vinorelbine (VB) and cisplatinum (CDDP) in locally advanced NSCLC (TOG-011 study). European Journal of Cancer 2001 37(6): S53.
48. Sezer M, Öztürk A, lvan A, Özkan M, Üskent N. The hemostatic changes in active pulmonary tuberculosis. Turk J Haematol ;18:2,95-100, 2001.
49. Etiz D, Üskent. Postradiation extramedullary lung plasmocytoma with pleural effsion. Journal of Balkan Union of Oncology 6:103-106, 2001.
50. Gnay A, Öztürk A. Budak T. Üskent N. Activated protein C resistance in polycythemia vera. Turkish Journal of Haematology. 18:157-164, 2001.
51. Öztürk A, Orhan B, Türken O, Etiz D, Yaylacı M, Üskent N. Acute Myeloblastic Leukemia Achieving Complete Remission with Amifostine Alone. Leukemia and Lymphoma 2002;43(2): 451-453.
52. Türken O, Etiz D, Orhan B, Çermik H, Yaylacı M, Öztürk A, Üskent N. Muscle metastasis as initial manifestation of epidermoid carcinoma of the lung. Clinical Oncology(Royal College of Radiologists(Great Britain))2002;14;129-131.
53. Türken O, Güney Y, Kandemir EG, Yaylacı M, Öztürk A, Orhan B, Üskent N. Prognostic importance of c-erb-2 (Her-2/neu) expression in early stage breast cancer, and its relationship with other prognostic factors. Turkish Journal of Oncology 17: 166-170, 2002.
54. Türken O. Sanal A. Yıldırım Ş. Üskent N. Investigation of Prognostic Value of Selenium in Breast Cancer. Turkish Journal of Oncology. 2002 17(3) 109-112.
55. Türken O. Değerlioğlu A. Üskent N. Diagnosis of iron-deficiency anemia and the role of transferrin receptor level in its distinction from chronic disease anemia. Turkish Journal of Hematology - Oncology. 121-5, 2002.
56. Türken O. Üskent N. Prognostic Value of c-Erb-B2 Expression in Early Stage Breast Cancer. Turkish Journal of Oncology. 17:166-17-, 2002.
57. Üskent N, Demirtaş S, Türken O. Survival from the precocious brain metastasis of the colon cancer. Turkish Journal of Cancer 33(3):154-157, 2003.
58. Üskent N. Natural History of Breast cancer,development, Risk factors,Distribution and epidemiology of the World. In Breast Cancer, 1. st edit. 2003:1-14.
59. Üskent N. General principles, preclinical and pioneering studies in cancer vaccines. Türkiye Klinikleri 2010:3(2):5-10.
60. Üskent N, Çökmez A, Atahan MK, Aksaz E, Güler N, Müslümanoğlu M, Özmen V. An electronic non-interventional pharmacovigilance study of early-stage breast cancer patients on adjuvant treatment with anastrozole (Arimidex®). Turkish Journal of Oncology; 2011, 26:55-60.
61. Ramadan S, Yapıcıer Ö, Kihtir S, Erdemir A, Doğan TH, Üskent N, Onat H, Çakmakçı M. Correlation of HER 2/neu Gene Amplification with Immunohistochemistry and Other Prognostic Factors in Breast Carcinoma. Turkish Journal of Pathology 2011 Sept;27(3):196-203.
62. Üskent N. Sezer M Belen G. Tamoxifen-Induced severe acute pancreatitis after a short-term therapy: a Case report. Turkish Journal of Oncology. 26(1):26-28. 2011.
Book chapters
1. Tecimer C, Üskent N. AIDS-related Tumors. Aydıner A, Topuz E. (Ed. ) Oncology Handbook, Turgut Yayıncılık A. Ş. Istanbul,2006: 520-30.
2. Üskent N. Tecimer C. Acute Leukemias. Oncology Handbook, Turgut Yayıncılık A. Ş. 2006:531-49.
3. Üskent N. Tecimer C. Chronic Myelocytic Leukemia Oncology Handbook, Turgut Yayıncılık,2006: 550-7.
4. Üskent N. Tecimer C. Chronic Lymphocytic Leukemia. Oncology Handbook, Turgut Yayıncılık,2006: 558-68.
5. Üskent N. Tecimer C. Hodgkin’s Lymphoma. Aydıner A, Topuz E. (Ed. ) Oncology Handbook, Turgut Yayıncılık, Istanbul,2006: 569-586.
6. Üskent N. Tecimer C. Kınay M. Non-Hodgkin’s Lymphomas Aydıner A, Topuz E. (Ed. )Oncology Handbook, Turgut Yayıncılık, Istanbul 2006:587-614.
7. Üskent N. Tecimer C. Myeloproliferative Diseases. Aydıner A, Topuz E. (Ed. ) Oncology Handbook, Turgut Yayıncılık A. Ş. Istanbul,2006: 637-45.
8 Üskent N. Blood and Blood Component Transfusions in Cancer Patients. Onat H, Mandel NM(Ed. ), In: Problems regarding Approach to the Cancer Patient, Diagnosis, Treatment and Follow-up. Revised 2nd Edition. Nobel Tıp Kitabevleri, İstanbul 2012.
9 Üskent N. Natural History of Brreast Cancer, Development, Risk Factors,Distribution and Epidemiology of the World. In: Breast Cancer 1. st Edit,İstanbul 2003,:1-14.
10 Üskent N. Prevention of Breast Cancer and Prophylaxis Studies in High-Risk Persons. In: Breast diseases. Editor Ünal G, Ünal H. Istanbul, Nobel Tıp Kitabevi 2001.
11 Üskent N. Cancer Prevention and Cancer Screening. In: Book of Internal Medicine. Editor Erol Ç. Nobel Yayınevi, 2011:7-15.
Congress papers
1. N. Üskent, M. Danacı, Z. Altınok, B. S. Cebeci, M. Özel: The Response of non-AIDS related Kaposi’s Sarcoma to Alpha 2B Interferon. 5. th National Antibiotic and Chemotherapy Congress, 1-4 May 1990, Antalya.
2. N. Üskent, M. Danacı, M. Yaylacı, M. Özel, H. Tor: Treatment of severe aplastic anemia with cyclosporine A. 22. nd National Hematology Congress. 21-25 October 1991, Istanbul.
3. M. Danacı, L. Dumanhan, M. Özel, N. Üskent: The effect of gemfibrozil in diabetic hyperlipidemias. 1991 National Diabetes Congress. 27-29 May 1991, Istanbul
4. Üskent N. Yaylacı M, Danacı M. Hematologic and Cytogenic Remissions Induced by Recombinant Alpha-Interferon 2b in CML. International Congress of Military Medicine, İstanbul, Sept. 18-25, 1993.
5. N. Üskent , M. Yaylacı , A. Öztürk , O. Türken : Treatment of chemotherapy induced anemia with recombinant human erythropoietin. Annals of Oncology. Lisbon, 1994.
6. Üskent N, Yaylacı M, A. Öztürk, O. Türken, M. Danacı: The result of intravenous high dose immunglobulin G administration in acute and chronic idiopatic thrombocytopenic purpura. Nato Military and Civil 3rd Blood Conference. İstanbul, 1994.
7. N. Üskent , M. Yaylacı , A. Öztürk : Treatment of chemotherapy induced severe thrombocytopenia with platelets obtained by continuous flow thrombocytopheresis. Nato Military and Civil 3rd Blood Conference. İstanbul, 1994.
8. N. Üskent, E. Ekşioğlu Demiralp, S. Ş. Özgün, T. Budak, O. Alpdoğan, A. Öztürk, T. F. Tuğlular, M. Aktan, M. Bayık, T. Akoğlu: Expression of CD 49d molecule on CLL Lymphocytes. British Journal of Haematology. 87, supplement 1, 1994.
9. N. Üskent, M. Yaylacı, A. Öztürk, F. Karslı: İntraarterial alpha interferon 2a through hepatic artery induces long term response in renal cell carcinoma metastatic to the liver. 5th İnternational Congress on Anti-Cancer Chemotherapy, Paris 1994.
10. M. Yaylacı, A. Öztürk, N. Üskent : A comparative study of antiemetic protocols. Growth and Therapy of Cancer. Budapest, 1994.
11. Özel M. Üskent N. Demonstration of the association of EBV with Hodgkin’s Lymphoma. 19. th ESMO Congress, Nov. 18-22,1994, Lisbon ,Portugal
12. Y. Küçükardalı, N. Haksever , S. Gül , A. Öztürk , H. Tor, N. Üskent : Leucocyte alkalen phosphatase activity in diabetic patients. Nato Military and Civil 3rd Blood Conference, İstanbul, 1994.
13. M. Yaylacı, Öztürk A, Türken O, Üskent N: Therapeutic efficacy of G-CSF in chemotherapy induced myelosuppression. Nato Military and Civil 3rd Blood Conference, İstanbul, 1994.
14. Öztürk, N. Üskent, M. Yaylacı: Severe thrombocytopenia complicating EBV infection. 13th Meeting of the İnternational Society of Haematology. İstanbul, 1995
15. A. Öztürk, N. Üskent, M. Yaylacı: Activated protein C resistance in malignancy. 13th Meeting of the İnternational Society of Haematology. İstanbul, 1995.
16. M. Özel, N. Üskent, M. Danacı, M. Yaylacı, H. Baloğlu: Demonstration of the relationship of Epstein-Barr Virus (EBV) with Hodgkin’s Disease and non-Hodgkin’s Lymphomas. XIth National Cancer Congress, 28 May-2 June 1995, Antalya.
17. A. Öztürk, G. Kandemir, M. Sezer, M. Yaylacı, N. Üskent: MAST cell leukemia. 1st Congress of Balkan Military Medical Committee, İstanbul, 1996.
18. A. Öztürk, G. Kandemir, M. Sezer, M. Yaylacı, N. Üskent: Pulmonary hemosiderosis. 1st Congress of Balkan Military Medical Committee, İstanbul, 1996.
19. A. Öztürk, G. Kandemir, M. Yaylacı, N. Üskent: CHOEP chemotherapy in intermediate and high grade non-Hodgkin lymphomas. Annals of Oncology. Lugano, 1996 {6-ICMLJune5-81996/12_posters-576}.
20. T. R. Evrenkaya, M. Akgün, A. Öztürk, M. Y. Tülbek,N. Üskent: The effects of intravenous essential aminoacid administration on the immun system of chronic hemodialysis patients. European Renal Association, European Dialysis and Transplant Association. Amsterdam, 1996.
21. A. Öztürk, M. Sezer, E. G. Kandemir, M. Yaylacı, N. Üskent: A comparative study of tropisetron versus granisetron in the control of cisplatin induced hyperemesis. 10th Mediterranean Congress of Chemotherapy. Antalya, 1996.
22. A. Öztürk, A. Günay, M. Sezer, G. Kandemir, M. Yaylacı, N. Üskent: Arterial thrombosis due to L-asparaginase in ALL. 10th Mediterranean Congress of Chemotherapy. Antalya, 1996.
23. A. Öztürk, M. Sezer, E. Kandemir, M. Yaylacı, N. Üskent: Antibiotic induced marrow failure during complete remission phase in ALL. 10th Mediterranean Congress of Chemotherapy. Antalya, 1996.
24. A. Öztürk, M. Sezer, E. Kandemir, M. Yaylacı, N. Üskent: Results of BEP regimen in the treatment of nonseminomatous germ cell testicular cancer. 10 Mediterranean Congress of Chemotherapy. Antalya, 1996.
25. Üskent N. Advances in Hematologcal Malignancies. 2. nd ISC Conference on Innovative Therapies, İstanbul,02-04 November, İstanbul, 2012
26. Üskent. N. Sezer M, Racatumomab Induced Complete Remission in a Patient with Treatment Refractory Metastatic Breast cancer. Congress of Cancer Immunology(CIMP),Mainz, Germany,2015.
27. Üskent N. Sezer M. Rituximaba bağlı Immün Kaynaklı Pneumonik İnfiltasyon. İmmüno-Onkoloji Kongresi, Antalya, 2015.
Presentations
1. Türken O, Orhan B, Öztürk A, Yaylacı M, Etiz D, Üskent N. A case of atypical chronic myelocytic leukemia developed after acute lymphoblastic leukemia treatment. XXVIIth National Hematology Congress and IVth Post-graduation Training Course, 11-13 November 1999 Istanbul. Poster No: P-027.
2. Türken O, Orhan B, Öztürk A, Etiz D, Üskent N. Orbital involvement in Non-Hodgkin’s lymphoma. Due to a case. XXVIIth National Hematology Congress and IVth Post-graduation Training Course, 11-13 November 1999 Istanbul. Poster No: P-028.
3. Türken O, Orhan B, Öztürk A, Yaylacı M, Etiz D, Üskent N. A case of acute myeloblastic leukemia who entered remission with amifostine. XXVIIth National Hematology Congress and IVth Post-graduation Training Course, 11-13 November 1999 Istanbul. Poster No: P-029.
4. Türken O, Etiz D, Orhan B, Öztürk A, Üskent N. Pernicious anemia in two young adults presenting with neurologic symptoms. XXVIIth National Hematology Congress and IVth Post-graduation Training Course, 11-13 November 1999 Istanbul. Poster No: P-067.
5. Türken O, Öztürk A, Orhan B, Etiz D, Üskent N. A case of acute lymphoblastic leukemia with aspergillosis. XXVIIth National Hematology Congress and IVth Post-graduation Training Course, 11-13 November 1999 Istanbul. Poster No: P-086.
6. Türken O, Öztürk A, Orhan B, Yaylacı M, Üskent N. The role of serum-soluble transferrin receptor in the distinction of iron-deficiency anemia and chronic disease anemia. XXVIIIth National Hematology Congress and Post-graduation Training Course, 1-4 November 2000 Izmir.
7. Türken O, Öztürk A, Orhan B, Yaylacı M, Üskent N. A case with thrombophilia resisting Warfarin (Coumadin) and heparin. XXVIIIth National Hematology Congress and Post-graduation Training Course, 1-4 November 2000 Izmir.
8. Orhan B, Türken O, Öztürk A, Uyanoğlu A, Etiz D, Yaylacı M, Üskent N. A case of Hodgkin’s Lymphoma with hepatocellular carcinoma and isolated bone metastases. XXVIIIth National Hematology Congress and Post-graduation Training Course, 1-4 November 2000 Izmir.
9. Öztürk A, Türken O, Orhan B, Uyanoğlu A, Yaylacı M, Üskent N. Correlation of the efficacy of pentoxifylline, cyclofloxacin and dexamethazone with amifostine in patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome. XXVIIIth National Hematology Congress and Post-graduation Training Course, 1-4 November 2000 Izmir.
10. Etiz D, Öztürk A, Türken O, Orhan B, Ardalı Y, Çermik H, Yaylacı M, Üskent N. Extramedullary plasmacytoma of the lung developed after radiotherapy. XXVIIIth National Hematology Congress and Post-graduation Training Course, 1-4 November 2000 Izmir.
11. Turken O, Orhan B, Öztürk A, Etiz D, Yaylacı M, Üskent N. Patients with myelodysplastic syndromes benefit from therapy with Amifostine, pentoxfylline and ciprofloxacin with dexamethasone. Congress of American Society of Hematology, Abstract book, Blood 98(11): 276b, 2001.
12. Hatemi G, Mandel N. Demir G, Üskent N. The effect of chemotherapy on peripheral blood mononuclear cell telomerase activity in breast and ovarian cancer patients. Proceeding of ESMO Abst. N0:66,19, 2002.
13. Üskent N. The Contribution of Subtypes of VEGF Inhibitors to Treatment in Non-small Cell Lung Cancers. Lung Cancers Congress. İzmir 16-19 October 2008.
14. Üskent N. Angiogenesis and Angiogenesis Inhibitors in Breast Cancer. National Breast Cancer Congress. Istanbul, October 24-26, 2008.
15. Üskent N. Molecular Guides in the Systemic Treatment of Metastatic Breast Cancer. 1st Blacksea Breast Cancer Congress, Samsun 2011.
16. Üskent N. Advances in Hematological Malignancies. 2. nd ISC Conference on Innovative Therapies,İstanbul,02-04 November, İstanbul 2012.
17. Üskent N. Signaling Pathways and Goal-oriented Treatments in Hematologic Malignancies. 4th National Lymphoma – Myeloma Congress, 3-5 May, Side 2013.
18. Üskent N. Genetics in Colo-rectal Cancer. 3rd. International Gastrointestinal Cancer Conference 13-15 December, Gloria Hotel, Antalya, 2013.
19. Üskent N. What is New in Advanced NSLC Treatment. 22. Annual Meeting of the Asian Society for cardiovascular&Thoracic Surgery(ASCVTS14). 04. 04. 2014, İstanbul. Congress Center, Harbiye İstanbul.
20. Üskent N. To Whom and How Should We Perform Neoadjuvant Systemic Treatment in Breast Cancer? 3rd Blacksea Breast Diseases Congress. 26-29 March, 2015 Samsun.
21. Üskent N. Treatments other than Transplantation in Relapse/Refractory Non-Hodgkin’s Lymphomas. Lymphoma-Myeloma Congress, Antalya, 10-12 April 2015.
22. Üskent N, Sezer M. Severe intra-articular hemorrhage that occurred during Sunitinib therapy in an asymptomatic patient with mild Factor WVB deficiency. National Cancer Congress, 22 -26 April 2015, Antalya.
23. Üskent N. Systemic Neo-Adjuvant treatment of Breast Cancer. International Breast Cancer Symposium. Anadolu Health Science Center Efes Auditorium, Gebze, Kocaeli,12. 09. 2015.
24. Üskent N. Systemic Therapies in Metastatic Brain Tumors. Multi-Disciplinary Neuro-Oncology Symposium. 06-07. 11. 2015. Hyatt Regency Hotel Istanbul.
25. Üskent. N. From Theory to Practice: Cancer Immunotherapy. International Symposium of Imunotherapy of CancerKarolinska Experience: Focusing On GBM and Pancreatic Cancers. Anadolu Health Science Center, Efes Auditorium, Gebze, Kocaeli. 06. 09. 2015
26. Üskent N. Targeted Treatments in Non-Hodgkin’s Lymphoma and Multiple Myeloma, Medical Oncology Society, Hematological Malignancies Course. Adana 07-09 November, 2015
Consultant in Editorial Boards:
1. Journal Of Turkish Oncology
2. Drugs
3. Journal of Advances in Modern Oncology Research(AMOR). PiscoMed Publishing Pte Ltd
Featured Cancer Articles